Ocam Protect

Quick links to important sections

Ocam Protect

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ocam Protect

Quick Facts

Property Description
Active ingredients Meloxicam and Esomeprazole
Form Oral preparation tablet
Pharmacological class NSAID and Proton Pump Inhibitor (PPI) combination
General purpose Pain relief with gastroprotection
Origin Synthetic compounds

What Type of Medicine is Ocam Protect?

Ocam Protect is a prescription-only medicine classified as a fixed-dose combination product that merges two distinct pharmacological actions into a single oral preparation. This composition places it into the high-level pharmacological categories of both an Anti-inflammatory agent and an Antiulcer agent, reflecting its established role in facilitating concurrent therapy for adult patients. The combination of therapeutic agents is intended to provide a strategic advantage when treating complex conditions.

Active Ingredients and Compositional Design

The drug's composition relies on two primary active ingredients, both of which are synthetic compounds: Meloxicam and Esomeprazole. Meloxicam is classified as a Selective cyclooxygenase-2 (COX-2) inhibitor, a subtype of the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. Esomeprazole belongs to the Proton Pump Inhibitor (PPI) class, acting as a potent gastric acid secretion inhibitor. This oral preparation tablet is typically engineered as a modified-release dosage form to ensure the appropriate delivery and temporal coordination of each component's distinct therapeutic effect.

General Purpose and Dual Mechanism of Benefit

The general purpose of the Ocam Protect formulation is to achieve effective relief through pain management while simultaneously implementing a strategy for risk reduction against gastrointestinal complications. The combination of an NSAID with a PPI is used to decrease the risk of upper gastrointestinal ulceration and bleeding. The medicine is designed to protect the stomach while treating symptoms. These fixed-dose combination products are utilized for treating symptoms of certain inflammatory conditions while protecting patients from NSAID-associated upper gastrointestinal effects. This dual-action approach means the medicine covers both the need for symptom relief and the need for stomach safety in one product.

What side effects are possible with Ocam Protect?

Possible Side Effects and Safety Information

Ocam Protect, which contains the active substance meloxicam, is a non-steroidal anti-inflammatory drug (NSAID) primarily associated with gastrointestinal, renal, and hepatic adverse reactions, consistent with its drug class. Factual safety information is drawn directly from governmental regulatory documentation.

Documented Adverse Reactions

Adverse reactions have been reported both occasionally and in very rare cases, generally occurring within the first week of treatment. These effects are typically transient but may be serious or fatal in rare instances.

Frequency System-Organ Class Involved Documented Adverse Reactions
Occasionally Gastrointestinal, General, Renal Loss of appetite, vomiting, diarrhea, lethargy, renal failure.
Very Rare Gastrointestinal, Hepatic Haemorrhagic diarrhoea, haematemesis (bloody vomit), gastrointestinal ulceration, elevated liver enzymes.

Contraindications and Safety Restrictions

The product is contraindicated and must not be used in animals with certain pre-existing conditions or circumstances, including:

  • Gastrointestinal disorders, such as irritation and haemorrhage.
  • Impaired hepatic, cardiac, or renal function.
  • Haemorrhagic disorders or known hypersensitivity to the active substance or excipients.
  • Pregnancy or lactation.

Furthermore, use should be avoided in any dehydrated, hypovolaemic (low blood volume), or hypotensive (low blood pressure) animal due to a potential risk of increased renal toxicity. Ocam Protect must not be administered concurrently with other NSAIDs or glucocorticosteroids, and a minimum 24-hour treatment-free period is required when transitioning from other anti-inflammatory therapies.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Ocam Protect overdose is based on the known risks of its active components, Meloxicam (an NSAID) and Esomeprazole (a PPI). Overdose manifestations are primarily linked to the NSAID component and range from mild to severe.

Documented Overdose Manifestations and Risks

Classification Official Regulatory Statement
Documented Symptoms Symptoms may include lethargy, somnolence, nausea, vomiting, and epigastric pain.
Severe Outcomes The official label documents potential for life-threatening outcomes, including acute renal failure, gastrointestinal bleeding, hepatic dysfunction, respiratory depression, and convulsions or coma.

Regulatory Mandates for Emergency Action

Overdose management is defined by regulatory bodies through specific, non-negotiable actions. No specific antidote is known for overdose of either the Meloxicam or Esomeprazole components. Treatment is documented as symptomatic and supportive. Procedures such as gastric lavage and the administration of activated charcoal should be considered shortly after ingestion to manage systemic exposure.

When Immediate Medical Help is Required

Regulatory documentation mandates seeking immediate medical attention or contacting a Poison Control Center right away if any overdose is suspected. Urgent medical help is required for the appearance of severe symptoms such as signs of bleeding, respiratory depression, or altered consciousness. Close observation and monitoring are required in overdose situations.

Therapeutic Uses of Ocam Protect

What Ocam Protect Treats: Main Uses and Benefits


This medication is used for the symptomatic relief of chronic inflammatory joint conditions in adults, specifically for conditions presenting with symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). The product's anti-inflammatory component is relevant for addressing symptoms such as pain, tenderness, swelling, and stiffness associated with these diseases.

The primary therapeutic relevance is its application within patient groups who require sustained anti-inflammatory and analgesic therapy but are at high risk of developing serious upper gastrointestinal complications. The combination is applied to help address the risk of developing gastric and duodenal ulcers or associated bleeding that can occur with the long-term use of traditional anti-inflammatory drugs. This medication supports symptomatic relief, which helps patients manage the pronounced burden of chronic joint pain and stiffness. This may assist with general functional stability and supports general well-being during symptomatic phases.


Quick Fact: Relief for Chronic Joint Discomfort

Property Description
Primary Focus Chronic Inflammatory Pain
Clinical Scenarios Long-term management of chronic arthritis symptoms in high-risk patients
Core Benefit Symptomatic relief with concurrent risk reduction

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Ocam Protect?

Regulatory documents define eligibility for Ocam Protect (Meloxicam/Esomeprazole) based on absolute contraindications and necessary restrictions concerning patient status and age. The medicine is indicated only for adult patients (generally 18 years of age) who require relief for chronic inflammatory joint conditions and are at high risk of developing NSAID-associated gastric ulcers.


Absolute Contraindications (Must Not Use)

Category Prohibited Population Regulatory Status
Allergy History Known hypersensitivity to either active ingredient or cross-reactive NSAID allergies (e.g., aspirin-sensitive asthma). Contraindicated
Cardiovascular/Surgical Patients in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery. Contraindicated
Active GI Disease Patients with active gastrointestinal bleeding, ulceration, or perforation. Contraindicated
Pregnancy (Late-Term) Use at or after 30 weeks gestation. Contraindicated
Severe Organ Function Patients with severe hepatic insufficiency (Child-Pugh Class C). Contraindicated

Restricted or Conditional Use

Use is not recommended in the pediatric population as safety and efficacy are not established for the fixed-dose combination. Similarly, the drug is not recommended for patients with moderate or severe renal insufficiency. Caution is advised for older adults due to increased risk of serious adverse events and for women trying to conceive due to associated reversible infertility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Ocam Protect, a combination of Meloxicam and Esomeprazole, is defined by interactions stemming from metabolic interference and additive pharmacodynamic risks. Government authorities classify these interactions into categories that mandate specific constraints for concurrent therapy.


Official Interaction Restrictions and Constraints

Co-administration with other non-aspirin NSAIDs is prohibited to avoid the cumulative risk of serious gastrointestinal adverse events. The combination is formally contraindicated with the antiviral agent Nelfinavir due to Esomeprazole reducing the drug's systemic exposure. Esomeprazole's activity as a CYP2C19 inhibitor means co-administration with Clopidogrel should be avoided, as this interaction reduces the formation of the antiplatelet agent’s active metabolite.

The Meloxicam component confers an increased risk of bleeding complications when combined with Anticoagulants. The product may elevate and/or prolong serum concentrations of drugs such as Lithium and Methotrexate. Furthermore, Esomeprazole’s effect of raising gastric pH can interfere with the absorption of medicines requiring an acidic environment, including Ketoconazole and Erlotinib.

Use with the herbal product St John's Wort should be avoided. The product is also not recommended in patients with severe hepatic insufficiency due to altered clearance of the active components.

Mechanism of Action

How Ocam Protect Works

This fixed-dose combination engages two distinct, yet functionally complementary mechanisms that modulate distinct biological pathways.

Modulating Inflammatory Pathways via Selective COX-2 Inhibition

This domain centers on the Cyclooxygenase-2 ( COX-2) enzyme, which is primarily responsible for producing pro-inflammatory prostaglandins at sites of elevated COX-2 activity. The anti-inflammatory component preferentially inhibits the activity of COX-2, a molecular step that directly reduces the output of inflammatory mediators and thereby decreases the sensitization threshold of peripheral nociceptive pathways.

Irreversible Blockade of Gastric Acid Secretion

The gastro-protective component irreversibly inhibits the Gastric H^+ / K^+-ATPase (Proton Pump), the terminal enzyme system in the parietal cells responsible for pumping hydrochloric acid ( HCl) into the stomach. This mechanism leads to a significant and prolonged suppression of gastric acidity, fundamentally altering the chemical environment within the stomach lumen.

Functional Complementarity and Mitigation of Mucosal Vulnerability

The two mechanisms exhibit functional synergy: the anti-inflammatory action carries a mechanistic risk to the gastric mucosal barrier via its effect on COX-1, whereas the acid-suppressing mechanism directly counteracts the reduction in mucosal defense caused by the anti-inflammatory mechanism. This complementary action supports the core mechanism without increasing the biological challenge to the gastric lining.

Dosage and Administration Information

How to Use Ocam Protect: Official Administration Guidelines

Ocam Protect is a fixed-dose combination product containing Meloxicam (NSAID) and Esomeprazole (PPI) designed for specific administration.


Administration Scope

Entity Instruction
Route of administration The medication is designed for oral use, administered as a tablet.
Dosing schedule The standard regimen is one tablet per day. The dose is fixed, commonly containing either 7.5 mg or 15 mg of the Meloxicam component, which should not exceed the maximum daily limit of 15 mg.
Timing in relation to meals The tablet must be taken at least 30 minutes before a meal for the gastroprotective component (Esomeprazole) to be optimally effective.
Preparation requirements The tablet must be swallowed whole with liquid. It must not be split, chewed, cut, or crushed, as this compromises the modified-release design of the dosage form.
Population adjustments Dose adjustments are typically specified for patients with moderate renal or hepatic impairment, often necessitating the lowest available dose (e.g., the 7.5 mg Meloxicam component) for long-term use.

Official Use Protocol

Official step sequence:

  • Take one tablet of Ocam Protect daily.
  • Ensure the dose is taken at least 30 minutes before consuming any food.
  • Swallow the tablet whole with liquid, avoiding any manipulation of the tablet.

This procedural structure defines the standardized, non-titrated approach to administering the combination drug. The precise oral route, frequency, and strict adherence to the pre-meal timing and tablet integrity are mandatory conditions to ensure the medicine is used as intended for chronic therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ocam Protect


Evidence for Symptomatic Relief of Chronic Joint Conditions

Research for this combination was studied for how it relates to outcomes related to chronic inflammatory joint conditions, which are conditions characterized by fluctuating or episodic manifestations. These studies included adult patients diagnosed with conditions such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). The research explored outcomes related to physical discomfort, monitoring patient-reported measures of pain and physical functioning. Studies examined how symptoms change over time when patients was observed in defined time intervals.


Evidence for Gastrointestinal Risk Reduction in High-Risk Patients

This area of the research framework studies the anti-inflammatory component in combination with the anti-ulcer component. Therefore, studies was observed in adult patient groups who are at high risk for developing NSAID-associated ulcers. The studies monitored the prevention of gastrointestinal lesions, using endoscopic examinations to detect the occurrence of ulcers in the stomach and small intestine. Findings indicate that the combination strategy was observed in some studies that also examined other anti-inflammatory strategies. Research also included dedicated Pharmacokinetic/Pharmacodynamic (PK/PD) studies that explored the medicine’s absorption profile and outcomes monitoring gastric acid levels.


Evidence Gaps and Areas of Uncertainty

The evidence structure has several known limitations that researchers acknowledge. Limited information for long-term outcomes means that while research has explored whether this medicine may relate to symptom changes and ulcer prevention in the short term, long-term effects are not fully established or well characterized. The overall profile of the combination relies on bridging data—meaning that the research base connects the established profiles of the two individual components with targeted studies on the fixed formulation. Few data are available for patients who have certain pre-existing health conditions alongside their arthritis, and the comparative evidence is lacking for a direct head-to-head comparison against every other combination strategy.

Key Studies & References

  1. Axsome Announces AXS-06 (Moseic Meloxicam And Esomeprazole) Meets Primary Endpoint In Phase I Clinical Trial (PK/PD study of the fixed combination)

Frequently Asked Questions (FAQ)

Common questions about Ocam Protect (FAQ)

Q: Is Ocam Protect a brand-new medication or a generic?

A: Ocam Protect is a fixed-dose combination product, meaning it contains two established medicines—Meloxicam and Esomeprazole—combined into one tablet. The product is registered and licensed under its unique brand name, Ocam Protect, but its components have been used separately for a long time.

Q: Does Ocam Protect have any long-term effects that people need to know about?

A: Official regulatory documents indicate that long-term use of the anti-inflammatory component (Meloxicam) is associated with warnings regarding potential risks to the cardiovascular system, gastrointestinal tract, and kidney function. For this reason, official product information advises that the medication be used at the lowest effective dose for the shortest necessary duration.

Q: Are there any common over-the-counter drugs that should be avoided when taking Ocam Protect?

A: Official labeling advises against the concomitant (simultaneous) use of Ocam Protect with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This includes common over-the-counter NSAIDs like ibuprofen or naproxen, due to the potential for an increased risk of side effects.

Q: How long does it typically take for Ocam Protect to start working?

A: The pain-relief component (Meloxicam) typically reaches its highest concentration in the blood within approximately 5–6 hours after administration. The acid-suppression component (Esomeprazole) begins working quickly to reduce acid, but it takes several days of consistent use to reach its full effect.

Q: If I miss a dose of Ocam Protect, what is the usual recommendation?

A: Patient guidelines often describe taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to avoid taking a double dose. Specific instructions are found in the official patient information leaflet.

Q: What are the most common reported side effects of Ocam Protect?

A: According to official documentation, the most common side effects reported in clinical studies typically include headache, diarrhea, abdominal pain, nausea, and flatulence (gas). Detailed information on all known adverse effects is available in the dedicated side effects section.

Q: Is it normal to feel a little dizzy when starting Ocam Protect?

A: The drug’s official labeling lists dizziness as a possible side effect of the anti-inflammatory component (Meloxicam). Patients should be aware of this possibility. If any side effect is severe or persistent, it is important to review the matter with a healthcare provider.

Q: What happens if I stop taking Ocam Protect suddenly?

A: Because Ocam Protect is not classified as an addictive substance, abruptly stopping the medication does not lead to physical withdrawal symptoms. However, the symptoms of the condition being treated, such as pain and inflammation, may return after cessation.

Q: Has Ocam Protect been studied in children?

A: Regulatory documents indicate that the Meloxicam component of the drug has been approved for use in children aged 2 years and older for the treatment of Juvenile Idiopathic Arthritis (JIA). The decision to use the Ocam Protect combination product in this population is made by the treating healthcare provider.

Q: Can Ocam Protect affect my sleep schedule?

A: Official product information notes that, rarely, the medicine may be associated with central nervous system side effects. These can include undesirable effects such as somnolence (drowsiness) or insomnia (difficulty sleeping).

Q: How long do most people stay on Ocam Protect treatment?

A: Ocam Protect is typically prescribed for managing the signs and symptoms of chronic conditions, such as arthritis. The total duration of treatment is determined by the prescribing healthcare provider based on the clinical assessment of the condition being treated and the patient's response.

Q: Does Ocam Protect interact with common vitamins or supplements?

A: The official documentation lists specific known drug interactions but does not typically provide a complete list for every vitamin or supplement. Therefore, it is generally important for patients to inform their healthcare provider of all supplements they take before starting this medicine.

Q: What kind of medical monitoring is usually required while on Ocam Protect?

A: Due to the drug's known safety profile, regulatory information advises that patients be monitored periodically. Monitoring often includes checking blood pressure and performing blood tests for kidney function (renal) and liver function (hepatic), especially during long-term use.

Q: Is Ocam Protect considered a controlled substance?

A: No, Ocam Protect is a Nonsteroidal Anti-inflammatory Drug (NSAID) combined with a Proton Pump Inhibitor (PPI). Neither of the components is classified as a controlled substance by major regulatory authorities like the DEA or FDA.

Q: Are there any studies comparing Ocam Protect to a placebo?

A: The approval of the medication is based on results from clinical trials, and official documents confirm that these trials commonly include studies that compare the drug's effects against a placebo (an inactive substance) to evaluate its efficacy.

Q: Do you need a special kind of prescription to get Ocam Protect?

A: Ocam Protect is generally classified as a prescription-only medication in most countries, meaning it must be obtained with a standard medical prescription from a licensed healthcare provider.

Q: Can Ocam Protect affect lab test results?

A: Official labeling indicates that the anti-inflammatory component (Meloxicam) may cause changes in certain laboratory tests. These changes can include elevated levels related to monitoring liver function (enzymes) and kidney function (creatinine or potassium levels).

Q: Is Ocam Protect known to cause changes in mood or behavior?

A: Official regulatory documents list psychiatric disturbances as rare or uncommon adverse effects associated with the drug components. These can include changes in mood such as nervousness, confusion, or other mood alterations.

Q: Can Ocam Protect be taken at any time of day?

A: Regulatory documents state the medication must be taken once daily and specify that it should be taken at least 30 minutes before a meal. As long as these conditions are met, the specific time of day (e.g., morning or evening) is not strictly mandated.

Q: What is the risk of developing a severe allergic reaction to Ocam Protect?

A: Official warnings note that the anti-inflammatory component (Meloxicam) has been associated with severe, potentially life-threatening allergic reactions, including anaphylactic reactions and serious skin conditions. It is specifically contraindicated in patients with a history of asthma, hives, or other known allergies to aspirin or any other NSAID.

Q: What is the purpose of the 'Protect' part of the drug name?

A: The name reflects the presence of the gastroprotective component (Esomeprazole). This part of the medicine is included specifically to reduce the risk of serious stomach and intestinal problems, such as ulcers and bleeding, which are potential side effects of the anti-inflammatory component (Meloxicam).

Q: Does Ocam Protect have a documented risk for liver or kidney issues?

A: Yes, official documentation includes boxed warnings and precautions for potential adverse effects on the liver (hepatotoxicity) and the kidneys (renal toxicity). These risks should be considered, especially with long-term use or in patients who already have underlying medical conditions.

Q: Does Ocam Protect interact with alcohol?

A: Official counseling information advises that combining Ocam Protect with alcohol may increase the risk of developing stomach bleeding. It may also potentially increase the risk of liver or kidney problems associated with the anti-inflammatory component.

Q: Is it possible to become dependent on Ocam Protect?

A: Ocam Protect is a combination of two non-addictive substances—an NSAID and a PPI. It is not classified as an addictive medication and does not cause physical dependence or withdrawal symptoms when stopped.

Q: What are the general safety warnings associated with Ocam Protect?

A: The official label carries prominent warnings regarding the potential for serious cardiovascular thrombotic events, which include the risk of heart attack and stroke. There are also warnings for serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines.

Q: If I have a history of heart problems, can I still use Ocam Protect?

A: The drug's anti-inflammatory component is contraindicated (must not be used) in the setting of coronary artery bypass graft (CABG) surgery. Official guidance notes it is generally avoided in patients who have had a recent heart attack due to the potential for increased risk.

Q: Are there any restrictions on driving or operating machinery while taking Ocam Protect?

A: Regulatory guidance advises caution if a person experiences side effects such as dizziness, somnolence (drowsiness), or blurred vision while taking this medicine. Official guidance advises against driving or operating machinery if a person experiences these effects.

Q: What are the official contraindications for Ocam Protect?

A: Official contraindications—situations where the drug must not be used—include known allergies to the drug's components or any other NSAID, pain management immediately following heart bypass surgery (CABG), and use during the last trimester of pregnancy.

Q: Does Ocam Protect have any known side effects that are delayed?

A: The official label cautions that serious gastrointestinal adverse events (bleeding, ulceration) and cardiovascular events may occur at any time during use. Crucially, these events may occur without warning symptoms, highlighting the potential for effects that are not immediately obvious.

Q: Why is Ocam Protect not recommended for certain patients?

A: The medication is not recommended for certain patients because of a known increased risk of serious adverse events. Examples include individuals with a history of aspirin-sensitive asthma, those recovering from heart bypass surgery (CABG), or women in the last trimester of pregnancy.

Q: Is it okay to store Ocam Protect in a bathroom cabinet?

A: Official guidance advises storing the medication at room temperature, away from excessive moisture and heat. Due to the significant fluctuations in humidity that occur in most bathrooms, storing the medicine in a bathroom cabinet is generally not recommended.

Q: How quickly does the benefit from Ocam Protect fade after stopping treatment?

A: The anti-inflammatory component (Meloxicam) has a relatively long half-life, meaning it is slowly eliminated from the body over time. Regulatory information suggests the effects are expected to diminish gradually over several days after treatment is stopped.

Q: Are there any groups of people for whom Ocam Protect may not work as well?

A: The labeling highlights that certain patient populations, such as the elderly or those with moderate kidney or liver impairment, may require careful dose adjustment. This is primarily to manage drug exposure and potential risks.

Q: Can Ocam Protect be taken with acid reflux medications?

A: Ocam Protect already contains a potent acid-reducing medicine (Esomeprazole, a PPI). Therefore, taking it with additional acid reflux medicines, such as H2-blockers or other PPIs, is generally not recommended by official guidance unless specifically advised by a healthcare provider.

Q: Where can I find the official FDA (or similar agency) labeling for Ocam Protect?

A: The official, detailed professional labeling (Prescribing Information) for the drug is publicly available on government websites. You can typically find this information on resources like the FDA’s Drugs@FDA site or the National Institutes of Health’s (NIH) DailyMed database.

Q: Do studies suggest Ocam Protect helps improve quality of life?

A: Clinical trials for the treatment of chronic conditions like arthritis often include secondary outcomes, such as measures of physical function, pain severity, and overall quality of life. These patient-reported outcomes (PROs) are part of the evidence reviewed during the regulatory approval process.

Q: What is the main ingredient in Ocam Protect?

A: Ocam Protect is a fixed-dose combination product containing two active ingredients: Meloxicam, which is the non-steroidal anti-inflammatory drug (NSAID) component, and Esomeprazole, which is the proton pump inhibitor (PPI) component.

Q: Are there different strengths or dosages of Ocam Protect available?

A: Yes, official labeling confirms the product is available in different strengths, which refers to the dose of the anti-inflammatory component. These are typically available containing either 7.5 mg or 15 mg of the Meloxicam component.

Q: Can Ocam Protect be used by older adults?

A: While older adults can use Ocam Protect, official documents advise careful consideration. Dose adjustments, often necessitating the lowest available dose, are specified for elderly patients, as they may have an increased potential for side effects.

Q: Is there any evidence about Ocam Protect use during pregnancy?

A: Regulatory documents advise against the use of the drug's anti-inflammatory component during the third trimester of pregnancy due to potential risk to the fetus. Information regarding use during earlier stages of pregnancy is available on the product labeling.

How should Ocam Protect be stored and disposed of?

The official storage and disposal guidelines for Ocam Protect, an oral tablet, are designed to maintain the product’s quality and ensure public safety.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, tightly closed, protected from light and moisture.
Prohibited Storage Do not refrigerate or freeze.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired medication must be handled according to regulatory requirements. Do not dispose of Ocam Protect by flushing it down a toilet or pouring it down a drain. Dispose of the tablets by using a medicine take-back program or following local regulations for safe pharmaceutical disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ocam Protect found in:

A-Z Index: